HB1207: The Ibogaine Treatment Study Bill is stalled in the HGO Committee! Please call members today and
ASK FOR A VOTE!
Contact info for House Government Operations (HGO) Committee members:
Treatment for opioid dependence, as well as healthcare policy designed to address the epidemic proportions of suffering individuals, have been monopolized by an industry with enough capital to create brilliant marketing and promotion strategies that have created a $1.4 billion opioid addiction treatment industry in the U.S., as of 2014 (Manalo, 2017).
“Interestingly, the pharmaceutical industry's response to this drug addiction crisis is more drugs” (Manalo, 2017)
Due to a lack of equally proportional funding for high profile marketing and lobbying strategies, other equally viable or promising alternative treatments, like Ibogaine therapy, have either struggled to gain a foothold in the treatment arena or remain virtually unheard of. This is simply unconscionable given the degree to which this problem is devastating our families and communities across Maryland, and hemorrhaging our hard-earned tax dollars in a futile attempt to meet the burgeoning capacity needs of our overwhelmed healthcare and justice systems.
It’s effectiveness in curing opiate addiction was first discovered in 1962, by Howard Lotsof, a heroin addict living in New York. Seeking a recreational hallucinogenic experience, he found that after a two day intense hallucinogenic ‘trip’, he no longer felt any cravings for heroin –even more incredibly, he had no withdrawal symptoms.
Since then, studies undertaken by leading research and academic facilities have corroborated Lotsof’s experience, demonstrating that ibogaine is an effective addiction interrupter for most substances including heroin, methadone, methamphetamine, cocaine, alcohol, and nicotine. With just one dose of the hallucinogen and a psychedelic journey that can last days, heroin addicts, alcoholics and cocaine users have reportedly found themselves completely free from their cravings –with none of the usual withdrawal symptoms.
Although medical use of ibogaine is currently not legal in the United States, it is currently used to treat opiate addiction in other countries, including Canada and Mexico. While 9 of the 28 countries presently in the European Union have similar classifications as the U.S., it is unregulated (neither officially approved nor illegal) in much of the rest of the world. New Zealand, Brazil, and South Africa have classified ibogaine as a pharmaceutical substance and restrict its use to licensed medical practitioners. This has led Americans who struggle with addiction to seek out international clinics or underground providers to receive treatment.
· Eliminates craving and withdrawal symptoms associated with opiate use disorder (Alper, 1999; Alper et al., 2012; Cloutier-Gill et al., 2016; Franciotti, 2013; Glick, 1991, 1999; Heink, 2017; Lotsof and Alexander, 2001; Mačiulaitis et al., 2008; Mash et al., 1995, 2000, 2001; Noller, 2016; Sheppard, 1994)
· Clinical trials have reported rates of abstinence at twelve month follow-up of between 20% (Brown & Alper, 2017), 24% (Bastiaans, 2004), 40% - 50% (Mash, 2016), and 57% (Noller, 2016). Other studies report that participants were either abstinent from all drug use, or had stopped use of primary and secondary drugs of choice (primary opiates) (Bastiaans, 2004)
· Ibogaine is not addictive (Koenig and Hilber, 2015; Ross, 2012)
· Perceived improvement in overall health by 58% of respondents (Bastiaans, 2004)
· Significant reductions in reported depression (Mash, 2012; Noller, 2016) by 100% of respondents (Bastiaans, 2004)
· Triggers recovery patterns for other psychological issues including anxiety disorders and post-traumatic stress disorder (Anderson, 1998; Bastiaans, 2004)
· Reduced criminal behavior (Bastiaans, 2004)
· Reported improvements in family relationships and social connectivity (Brown and Alper, 2017; Noller, 2016) in 88% of respondents (Bastiaans, 2004)
· Limited potential for abuse due to nausea and vomiting (Alper et al, 2012), and its propensity for facilitating emotionally unsettling and uncomfortable memories during therapy (Donnelly, 2011)
· If not dosed or administered correctly, it may cause cardiac arrest or seizures (Alper et al., 2012; Breuer et al, 2015; Hoelen, 2009; Jacobson, 2017; Maas, 2006; Noller, 2016;) –A total of 27 deaths have been reported globally since Ibogaine’s use as an anti-addictive medication (Litjens, 2016)
· ‘Waking dreams’ that may be unpleasant or emotionally uncomfortable (Taylor, 2017)
· Hampers muscle coordination during therapy (Taylor, 2017)
· May induce periods of nausea and vomiting during therapy (Breuer et al, 2015; Taylor, 2017)